BioTime (NYSE: BTX) and its subsidiary OncoCyte Corporation announced initial data from a large, prospective clinical study that showed the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE